[Skip to Content]
[Skip to Content Landing]
Comment & Response
April 25, 2017

Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis

Author Affiliations
  • 1Acute Vascular Imaging Centre, University of Oxford, Oxford, United Kingdom
JAMA. 2017;317(16):1690-1691. doi:10.1001/jama.2017.3443

To the Editor The Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV) trial1 was designed to determine the effects of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition with evolocumab (in statin-treated patients) on progression of coronary atherosclerosis, calculated as the change in PAV.